摘要
目的观察利拉鲁肽对肥胖2型糖尿病患者血清抵抗素(Resistin)、内脂素(Visfatin)水平的影响,分析影响两者下降的相关因素。方法将80例肥胖2型糖尿病患者随机分为二甲双胍组(M组,40例,门冬胰岛素30联合二甲双胍2 000 mg/d)和利拉鲁肽组(L组,40例,门冬胰岛素30联合利拉鲁肽1.2~1.8 mg/d),观察周期为12周。结果两组患者治疗后FPG、2 h PG、HA1C、HMOA-IR、内脂素较治疗前后比较差异有统计学意义(P<0.05或P<0.01),L组BMI、WC、TG、TC、抵抗素水平较治疗前亦有下降(P<0.05)。两组ΔBMI、ΔWC、ΔTG、ΔC、ΔHMOA-IR、ΔResistin、ΔVisfatin差异有统计学意义(P<0.05或P<0.01);相关分析显示,M组和L组ΔResistin与ΔTC正相关;M组ΔVisfatin与ΔBMI、ΔWC、ΔHMOA-IR正相关,L组ΔVisfatin与ΔBMI、ΔHA1C、ΔWC、ΔHMOA-IR正相关;多因素相关分析显示,M组和L组ΔResistin的影响因素均为ΔTC;M组和L组ΔVisfatin的影响因素分别为ΔWC和ΔWC、ΔHMOA-IR。结论利拉鲁肽可降低抵抗素和内脂素水平。
Objestive To observe the effect of liraglutide on serum resistin and alfatin levels on obese type 2 diabetic patients, and to analysis the factors influencing both decline. Methods 80 cases of obese patients with type 2 diabetes were divided into metformin group（Group M, 40 cases, insulin aspart 30 combined with metformin 2 000 mg/d） and the liraglutide group（Group L, 40 cases of insulin aspart 30 combined with liraglutide 1.2-1.8 mg/d）. The observation period was 12 weeks. Results The difference of FPG, 2 h PG, HA1 C, HMOA-IR, alfatin before and after treatment was statistically significant（P〈0.05 or P〈0.01）. L group BMI, WC, TG, TC, resistinwere also falling from before（P〈0.05）. The Δvisfatin in group M was positively related to ΔBMI, ΔWC and ΔHMOA-IR. The Δvisfatin in group L was positively related to ΔBMI, ΔHA1 C, ΔWC and ΔHMOA-IR. Multivariate correlation analysis showed that the influence factors of Δresistin in group M and L group were ΔTC. The influence factor of Δvisfatin in group M was ΔWC. ΔWC andΔHMOA-IR in group L were the factors affecting Δvisfatin. Conclusion Liraglutide could decrease the serum resistin and visfatin levels.
作者
徐滨华
李征寒
王立平
李姗姗
XU Binhua;LI Zhenghan;WANG Liping;LI Shanshan(Department of Endocrinology,First Hospital of Harbin,Harbin Heilongjiang 150010,China)
出处
《中国卫生标准管理》
2018年第13期85-88,共4页
China Health Standard Management
基金
黑龙江省哈尔滨市应用技术研究与开发项目(2015RAXYJ057)
